A5090740287- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Endometriosis Research and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- RNA Interference and Gene Delivery
- Uterine Myomas and Treatments
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer Mechanisms and Therapy
- BRCA gene mutations in cancer
- Sarcoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Cancer-related Molecular Pathways
- Ethics in Clinical Research
- Erythropoietin and Anemia Treatment
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2015-2024
Kettering University
2000-2021
Roswell Park Comprehensive Cancer Center
2004-2020
The University of Texas MD Anderson Cancer Center
2020
Women's Cancer Center of Nevada
2020
NRG Oncology
2020
University of Cincinnati
2020
Sidney Kimmel Comprehensive Cancer Center
2020
Johns Hopkins University
2020
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for support tool that distills the implications associated with specific mutation events into standardized and easily interpretable format. To this end, we developed OncoKB, expert-guided precision oncology knowledge base.
Purpose There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes limited. Methods We randomly assigned patients receiving outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center report 12 common symptoms via tablet computers or receive usual consisting the discretion clinicians. Those with home received weekly e-mail prompts between visits. Treating...
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response gemcitabine plus docetaxel among patients with LMS. PATIENTS AND METHODS: Patients unresectable of uterine (n = 29) or other 5) primary sites who did not respond zero two prior regimens were enrolled onto a phase II study 900 mg/m 2 intravenously (IV) on days 1 and 8 100 IV day granulocyte colony-stimulating factor given...
Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as a key component of breast and gynecologic cancer risk-reduction for women with BRCA1 BRCA2 mutations. Despite 17% to 39% all BRCA mutation carriers having in BRCA2, no prospective study date evaluated the efficacy RRSO prevention BRCA-associated (ovarian, fallopian tube or primary peritoneal) when are analyzed separately from carriers.A total 1,079 30 years age older ovaries situ deleterious were enrolled onto follow-up...
This selection from the NCCN Guidelines for Ovarian Cancer focuses on less common ovarian histopathologies (LCOHs), because new algorithms were added LCOHs and current revised 2016 update. The include clear cell carcinomas, mucinous grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. also carcinosarcomas (malignant mixed Müllerian tumors of ovary), borderline (also known as low malignant potential tumors), sex cord-stromal tumors, germ tumors.
Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated phase 3 investigation.
Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety in vivo immunogenicity of synthetic overlapping long (OLP) from a human tumor self-antigen, we conducted phase I clinical trial with OLP cancer-testis antigen NY-ESO-1 various adjuvant combinations.Twenty-eight patients advanced ovarian cancer second or third remission were enrolled sequentially three cohorts received at least one...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as which molecular alterations are clinically actionable. To quantify expansion clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with MSK-IMPACT assay using two temporally distinct versions OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, observed an increase 8.9% 31.6% fraction harboring standard...
Purpose Tracking symptoms related to treatment toxicity is standard practice in routine care and during clinical trials. Currently, clinicians collect symptom information via complex often inefficient mechanisms, but there growing interest collecting outcome directly from patients. Patients Methods The National Cancer Institute Common Terminology Criteria for Adverse Events schema seven common was adapted into a Web-based patient-reporting system, accessible desktop computers outpatient...
PURPOSE: To evaluate the prognostic significance of a bone scan index (BSI) based on weighted proportion tumor involvement in individual bones, relation to other factors and survival patients with androgen-independent prostate cancer. PATIENTS AND METHODS: Baseline radionuclide scans were reviewed 191 assessable disease who enrolled onto an open, randomized trial liarozole versus prednisone. The extent skeletal was assessed by scoring each using BSI independently according number metastatic...
The androgen receptor (AR) is a structurally conserved member of the nuclear superfamily. amino-terminal domain required for transcriptional activation and contains region polyglutamine encoded by CAG trinucleotide repeats. In humans, number repeats polymorphic; average 22 in Caucasian males. Expansion AR has clinical implications human disease. As influences prostate cancer growth, polymorphisms repeat length may affect course patients with cancer. To test an association between parameters...
These NCCN Guidelines Insights focus on the major updates for 2012 Clinical Practice in Oncology (NCCN Guidelines) Ovarian Cancer by describing how and why new recommendations were made. The 6 update topics selected based recent important guidelines debate among panel members about clinical trials, include: 1) screening, 2) diagnostic tests assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) adjuvant bevacizumab combination with 5) therapy recurrent disease, 6)...
Anemia is a common condition in patients with cancer, and its correction through either transfusion packed red blood cells or the administration of erythropoiesis-stimulating agents (ESAs) supportive care measure. The purpose guidelines to operationalize evaluation treatment anemia cancer enable clinicians evaluate options context risks benefits. updated include number important changes that respond new FDA recommendations limiting use ESAs patients. Updates also tables on benefits versus...
Abstract Purpose: Folate receptor α expression is highly restricted in normal adult tissues but upregulated a wide range of human cancer types, including epithelial ovarian cancer. Farletuzumab, humanized monoclonal antibody against folate α, has shown antitumor activity and favorable toxicity preclinical evaluation. This phase I, dose-escalation study was conducted to determine the safety weekly i.v. farletuzumab establish maximum tolerated dose (MTD). Experimental Design: Patients with...
To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer first clinical remission.Patients International Federation of Gynecology Obstetrics stage III to IV complete remission after primary surgery platinum- taxane-based chemotherapy were randomly assigned at a ratio 2:1 phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo was administered as 1-mL suspension once every...
Abstract Purpose: Advanced-stage endometrial cancers have limited treatment options and poor prognosis, highlighting the need to understand genetic drivers of therapeutic vulnerabilities and/or prognostic predictors. We examined whether prospective molecular characterization recurrent metastatic disease can reveal grade histology-specific differences, facilitating enrollment onto clinical trials. Experimental Design: integrated sequencing IHC data with detailed histories for 197 tumors,...
Hedgehog pathway inhibition has been suggested as a potential maintenance treatment approach in ovarian cancer through disruption of tumor-stromal interactions. Vismodegib is an orally available inhibitor with clinical activity advanced basal cell carcinoma and medulloblastoma. This phase II, randomized, double-blind, placebo-controlled trial was designed to provide preliminary estimate efficacy patients second or third complete remission (CR).Patients recurrent epithelial ovarian, fallopian...